<DOC>
	<DOCNO>NCT01014104</DOCNO>
	<brief_summary>This study prospective randomize clinical control trial ass efficacy Methylprednisolone prevent ovarian hyper stimulation syndrome vitro fertilization ( IVF ) cycle .</brief_summary>
	<brief_title>Administration Methylprednisolone Prevention Ovarian Hyper Stimulation Syndrome</brief_title>
	<detailed_description>Ovarian hyper stimulation syndrome serious complication ovarian stimulation might life threaten severe form . Since still definite cure syndrome , prevention consider essential vital issue . The objective study determine effect Methylprednisolone prevent ovarian hyper stimulation syndrome IVF cycle . The study population comprises infertile patient diagnosis polycystic ovarian syndrome undergo in-vitro fertilization . The PCO subject recognize base Rotterdam criterion inclusive presence least 2 sign oligomenorrhea , hyper androgynism ( clinical laboratory ) , LH/FSH &gt; 2 ovarian morphological evidence Doppler ultrasound . The existence 20 follicle ovary E2 concentration &gt; 4000 pg/ml consider OHSS risk factor . In study eligible patient randomly allocate two study group computerize randomization method : Treatment group ( case ) administer 16 mg Methylprednisolone initiate first day stimulation taper first pregnancy test ( day 13 embryo transfer ) . Furthermore , patient receive bolus IV dose methylprednisolone , 1g day egg collection embryo transfer . Patients control group receive treatment glucocorticoid . If group confront every kind high risk sign symptom , undergo coast gonadotropin withdrawal treatment strategy . The presence OHSS define accordance Golan 5 grade system woman least grade 2 classification ( Mild ) consider OHSS case experience abdominal distention discomfort , nausea vomit and/or diarrhea enlargement ovary ( 5-12cm ) . In Moderate form , ultrasound evidence ascites observe severe OHSS accompany clinical sign ascites , hydrothorax , breathe disorder , hemoconcentration , coagulopathy renal perfusion decrease .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Poly Cystic Ovarian Syndrome patient Indication IVF/ICSI Long Protocol ovarian stimulation Basal FSHâ‰¥10 Normal BMI ( 2025 ) physical health Allergy GnRH analogue , FSH corticosteroids presence heart failure , recent myocardial infarction Hypertension Diabetes mellitus epilepsy glaucoma hypothyroidism hepatic failure osteoporosis peptic ulceration renal impairment Using drug interaction corticosteroid</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Ovarian hyper stimulation syndrome</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>IVF</keyword>
</DOC>